Page last updated: 2024-08-24

saterinone and Chronic Disease

saterinone has been researched along with Chronic Disease in 1 studies

*Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baumann, G; Eichner, E; Iven, H; Kieback, AG; Ruckdeschel, W; Stolzenburg, K1

Other Studies

1 other study(ies) available for saterinone and Chronic Disease

ArticleYear
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
    International journal of cardiology, 2003, Volume: 91, Issue:2-3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Blood Platelets; Blood Pressure; Chronic Disease; Creatine Kinase; Creatinine; Cyclic Nucleotide Phosphodiesterases, Type 3; Diastole; Heart Atria; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Pyridones; Statistics as Topic; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vascular Resistance

2003